| Yang, Jin Mo |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
NCT05188989: Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction. |
|
|
| Completed | 3 | 765 | RoW | TPN171H 2.5mg group, Simmerafil, TPN171H 5mg group, TPN171H 10mg group, Placebo group | Vigonvita Life Sciences | Erectile Dysfunction | 02/23 | 02/23 | | |
HER2CLIMB-02, NCT03975647: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
|
|
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc. | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT05429684: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer |
|
|
| Recruiting | 3 | 120 | RoW | Trastuzumab, herceptin；Inetetamab, Pertuzumab, Perjeta, Nab paclitaxel, Abraxane, Pyrotinib, SHR-1258, Capecitabine, T-DM1, Trastuzumab Emtansine, Everolimus, RAD001, CDK4/6 inhibitor, Palbociclib；, AI, Letrozole, Anti-PD-1 monoclonal antibody, Sintilimab | First Affiliated Hospital Xi'an Jiaotong University | HER2+ Breast Cancer | 02/24 | 02/24 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
BCTOP-L-A01, NCT05891093: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer |
|
|
| Recruiting | 3 | 766 | RoW | Fluzoparib, Anastrozole, Letrozole, Exemestane, Tamoxifen, Toremifene, Abemaciclib, LHRH agonist | Fudan University | Breast Cancer | 05/28 | 05/31 | | |
BCTOP-T-A03, NCT05909332: Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients |
|
|
| Recruiting | 3 | 548 | RoW | Antivascular therapy, Chemotherapy | Fudan University | Breast Cancer, Triple Negative Breast Cancer | 05/29 | 05/31 | | |
OPTIMAL, NCT03315364: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy |
|
|
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
| Recruiting | 2 | 29 | RoW | Cadonilimab, AK-104 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Cervical Cancer | 10/25 | 10/27 | | |
NCT05429294: Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038 |
|
|
| Recruiting | 2 | 209 | RoW | Pyrotinib, Trastuzumab, Albumin paclitaxel | First Affiliated Hospital Xi'an Jiaotong University | HER2-positive Breast Cancer | 05/24 | 10/24 | | |
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 42 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 06/26 | 06/28 | | |
NCT05914857: Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients |
|
|
| Not yet recruiting | 2 | 120 | RoW | Dapagliflozin 10mg Tab, Dapagliflozin Tablets, lifestyle interventions | Yangjin, Peking University Third Hospital | Prediabetic State, Impaired Fasting Glucose, Impaired Glucose Tolerance | 06/25 | 12/25 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT05581888: Visual Performance of Functional Intraocular Lenses in Cataracts |
|
|
| Active, not recruiting | N/A | 62 | RoW | trifocal intraocular lens | Eye & ENT Hospital of Fudan University | High Myopia, Cataract | 06/21 | 03/23 | | |
NCT04668703: Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema |
|
|
| Not yet recruiting | N/A | 40 | NA | Conbercept intravitreal injection | Eye & ENT Hospital of Fudan University | Diabetic Macular Edema, Diabetic Retinopathy, Cataract Diabetic | 11/21 | 01/22 | | |
NCT05530473: Combined Capsular Tension Ring and IOL Implantation for Management of Cataracts |
|
|
| Completed | N/A | 200 | RoW | capsular tension ring, capsular tension ring (ACPi-11; Bausch&Lomb) | Eye & ENT Hospital of Fudan University, National Natural Science Foundation of China | Intraocular Lens Rotation, Capsular Tension Ring | 12/22 | 03/23 | | |
NCT05783063: iTBS for Increased Appetite Induced by Antipsychotics |
|
|
| Recruiting | N/A | 60 | RoW | Active iTBS, Sham iTBS | Central South University | Schizophrenia | 08/25 | 12/25 | | |
NCT05797298: Toric Intraocular Lens (IOL) Implantation for Management of Cataracts |
|
|
| Recruiting | N/A | 3000 | RoW | | Eye & ENT Hospital of Fudan University | Toric Intraocular Lens Stability, Visual Quality | 03/24 | 05/24 | | |
NCT06331923: Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Diabetic Patients |
|
|
| Recruiting | N/A | 10168 | RoW | Continuous glucose monitoring (CGM) device | Beijing Tsinghua Chang Gung Hospital, Peking University International Hospital, Wang Jing Hospital, ZhuHai Hospital, Beijing Hospital, Siyang County Hospital of Traditional Chinese Medicine, Second Hospital of Shanxi Medical University, Henan Provincial Chest Hospital, Fuzhou First Hospital, Pinggu Hospital of Beijing Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Mindong Hospital of Ningde, The Fifth Hospital of Xiamen, People's Hospital of Ningxia Hui Autonomous Region, The First People's Hospital of Changzhou, The Fifth hospital of Deyang, Suzhou Municipal Hospital, Tang-Du Hospital, Yiyang Central Hospital, First Affiliated Hospital of Xinjiang Medical University, Peng Ding Shan Shi Zhong Yi Yi Yuan, Yueyang Central Hospital, The First People's Hospital of Lianyungang, Haimen District Traditional Chinese Medicine Hospital, The 910th Hospital, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Beijing Tiantan Hospital, Affiliated Hospital of Jiangsu University, Liaocheng People's Hospital, Beijing Chao Yang Hospital, Jilin City Hospital of Chemical Industry, Creen Hospital-465, Wuhan Central Hospital, Air Force Military Medical University, China, Shanghai Tong Ren Hospital, Beijing Anzhen Hospital, Emergency General Hospital, Beijing Tongren Hospital, Civil Aviation General Hospital, Peking University Shougang Hospital, The First Affiliated Hospital of Anhui Medical University, Chinese PLA Central Hospital | Comprehensive Complication Index | 10/25 | 12/25 | | |
| Recruiting | N/A | 20000 | RoW | | Evidence Based Cataract Study Group | Cataract, High Myopia | 12/26 | 12/30 | | |
NCT06092164: Visual Outcomes of Functional Intraocular Lenses in Cataracts |
|
|
| Not yet recruiting | N/A | 20000 | NA | | Eye & ENT Hospital of Fudan University | Cataract, Visual Quality | 12/29 | 12/31 | | |
| Not yet recruiting | N/A | 500 | RoW | | Peking University Third Hospital | Type 1 Diabetes | 01/32 | 01/32 | | |
| Recruiting | N/A | 150 | RoW | | Eye & ENT Hospital of Fudan University, National Natural Science Foundation of China | Cataract, Pathogenesis | 12/23 | 12/25 | | |
